Antonio Bueno-Nava

Dr. Antonio Bueno-Nava

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Animals
Verified
Journal Article
Open access
PDF file
AVAntonio Verduzco-Mendoza
Antonio Verduzco-Mendoza
ABAntonio Bueno-Nava
Antonio Bueno-Nava
Dehua WangDehua Wang
Dehua Wang
JMJulio Martinez-Burnes
Julio Martinez-Burnes
Adriana OlmosAdriana Olmos
Adriana Olmos
Daniel Mota-RojasDaniel Mota-Rojas
Daniel Mota-Rojas
Evaluating laboratory animals’ health and thermostability are fundamental components of all experimental designs. Alterations in either one of these parameters have been shown to trigger physiological changes that can compromise the welfare of the species and the replicability and robustness of the results obtained. Due to the nature and complexity of evaluating and managing the species involved in research protocols, non-invasive tools such as infrared thermography (IRT) have been adopted to quantify these parameters without altering them or inducing stress responses in the animals. IRT technology makes it possible to quantify changes in surface temperatures that are derived from alterations in blood flow that can result from inflammatory, stressful, or pathological processes; changes can be measured in diverse regions, called thermal windows, according to their specific characteristics. The principal body regions that were employed for this purpose in laboratory animals were the orbital zone (regio orbitalis), auricular pavilion (regio auricularis), tail (cauda), and the interscapular area (regio scapularis). However, depending on the species and certain external factors, the sensitivity and specificity of these windows are still subject to controversy due to contradictory results published in the available literature. For these reasons, the objectives of the present review are to discuss the neurophysiological mechanisms involved in vasomotor responses and thermogenesis via BAT in laboratory animals and to evaluate the scientific usefulness of IRT and the thermal windows that are currently used in research involving laboratory animals.

12 September 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AAAlfonso Alfaro-Rodriguez
Alfonso Alfaro-Rodriguez
SRSamuel Reyes-Long
Samuel Reyes-Long
Ernesto Roldan-ValadezErnesto Roldan-Valadez
Ernesto Roldan-Valadez
MTMaykel González Torres
Maykel González Torres
HJHerlinda Bonilla Jaime
Herlinda Bonilla Jaime
JCJosé Luis Cortes-Altamirano
José Luis Cortes-Altamirano
Fibromyalgia (FM) is a disorder characterized by widespread chronic pain, significant depression, and various neural abnormalities. Recent research suggests a reciprocal exacerbation mechanism between chronic pain and depression. In patients with FM, dysregulation of tryptophan (Trp) metabolism has been identified. Trp, an essential amino acid, serves as a precursor to serotonin (5-HT), a neuromodulator that influences mood, appetite, sleep, and pain perception through the receptors 5-HT1, 5-HT2, and 5-HT3. Additionally, Trp is involved in the kynurenine pathway, a critical route in the immune response, inflammation, and production of neuroactive substances and nicotinamide adenine dinucleotide (NAD+). The activation of this pathway by pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α) and interferon gamma (IFN-γ), leads to the production of kynurenic acid (KYNA), which has neuroprotective properties, and quinolinic acid (QA), which is neurotoxic. These findings underscore the crucial balance between Trp metabolism, 5-HT, and kynurenine, where an imbalance can contribute to the dual burden of pain and depression in patients with FM. This review proposes a novel therapeutic approach for FM pain management, focusing on inhibiting QA synthesis while co-administering selective serotonin reuptake inhibitors to potentially increase KYNA levels, thus dampening pain perception and improving patient outcomes.

10 June 2010 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
ABAntonio Bueno-Nava
Antonio Bueno-Nava
RGRigoberto Gonzalez-Pina
Rigoberto Gonzalez-Pina
AAAlfonso Alfaro-Rodriguez
Alfonso Alfaro-Rodriguez
VNVladimir Nekrassov-Protasova
Vladimir Nekrassov-Protasova
ADAlfredo Durand-Rivera
Alfredo Durand-Rivera
FAFructuoso Ayala-Guerrero
Fructuoso Ayala-Guerrero

Verified
Journal Article
Open access
PDF file
SRSamuel Reyes-Long
Samuel Reyes-Long
JCJose Luis Cortés-Altamirano
Jose Luis Cortés-Altamirano
Cindy BandalaCindy Bandala
Cindy Bandala
KAKarina Avendaño-Ortiz
Karina Avendaño-Ortiz
HBHerlinda Bonilla-Jaime
Herlinda Bonilla-Jaime
AAAlfonso Alfaro-Rodriguez
Alfonso Alfaro-Rodriguez
The ongoing pandemic of COVID-19 has caused more than 6.7 million tragic deaths, plus, a large percentage of people who survived it present a myriad of chronic symptoms that last for at least 6 months; this has been named as long COVID. Some of the most prevalent are painful symptoms like headache, joint pain, migraine, neuropathic-like pain, fatigue and myalgia. MicroRNAs are small non-coding RNAs that regulate genes, and their involvement in several pathologies has been extensively shown. A deregulation of miRNAs has been observed in patients with COVID-19. The objective of the present systematic review was to show the prevalence of chronic pain-like symptoms of patients with long COVID and based on the expression of miRNAs in patients with COVID-19, and to present a proposal on how they may be involved in the pathogenic mechanisms of chronic pain-like symptoms. A systematic review was carried out in online databases for original articles published between March 2020 to April 2022; the systematic review followed the PRISMA guidelines, and it was registered in PROSPERO with registration number CRD42022318992. A total of 22 articles were included for the evaluation of miRNAs and 20 regarding long COVID; the overall prevalence of pain-like symptoms was around 10 to 87%, plus, the miRNAs that were commonly up and downregulated were miR-21-5p, miR-29a,b,c-3p miR-92a,b-3p, miR-92b-5p, miR-126-3p, miR-150-5p, miR-155-5p, miR-200a, c-3p, miR-320a,b,c,d,e-3p, and miR-451a. The molecular pathways that we hypothesized to be modulated by these miRNAs are the IL-6/STAT3 proinflammatory axis and the compromise of the blood–nerve barrier; these two mechanisms could be associated with the prevalence of fatigue and chronic pain in the long COVID population, plus they could be novel pharmacological targets in order to reduce and prevent these symptoms.

1 September 2013 in Neuroscience Letters
Verified
Journal Article
Closed access
AAAlfonso Alfaro-Rodriguez
Alfonso Alfaro-Rodriguez
MAMaría Alonso-Spilsbury
María Alonso-Spilsbury
EAEmilio Arch-Tirado
Emilio Arch-Tirado
RGRigoberto Gonzalez-Pina
Rigoberto Gonzalez-Pina
JAJosé-Antonio Arias-Montaño
José-Antonio Arias-Montaño
ABAntonio Bueno-Nava
Antonio Bueno-Nava

1 July 2016 in Neuropharmacology
Verified
Journal Article
Closed access
GAGuillermo Aquino-Miranda
Guillermo Aquino-Miranda
JEJuan Escamilla-Sánchez
Juan Escamilla-Sánchez
RGRaúl González-Pantoja
Raúl González-Pantoja
ABAntonio Bueno-Nava
Antonio Bueno-Nava
JAJose-Antonio Arias-Montaño
Jose-Antonio Arias-Montaño